Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lung Neoplasms | 160 | 2023 | 509 | 16.290 |
Why?
|
Tomography, X-Ray Computed | 30 | 2021 | 698 | 4.650 |
Why?
|
Mass Screening | 32 | 2023 | 168 | 4.400 |
Why?
|
Early Detection of Cancer | 14 | 2023 | 90 | 3.450 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 40 | 2016 | 228 | 2.490 |
Why?
|
Tomography, Spiral Computed | 15 | 2014 | 25 | 2.040 |
Why?
|
Carcinoma, Small Cell | 42 | 2005 | 50 | 1.990 |
Why?
|
Biomarkers, Tumor | 28 | 2010 | 184 | 1.800 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 3 | 2021 | 45 | 1.710 |
Why?
|
Humans | 188 | 2023 | 25692 | 1.530 |
Why?
|
Antibodies, Monoclonal | 38 | 1999 | 185 | 1.440 |
Why?
|
Smoking | 14 | 2015 | 165 | 1.170 |
Why?
|
Emphysema | 2 | 2023 | 4 | 1.070 |
Why?
|
Drug Design | 6 | 2013 | 23 | 1.050 |
Why?
|
Multiple Pulmonary Nodules | 2 | 2014 | 12 | 0.940 |
Why?
|
Peptides | 20 | 1997 | 104 | 0.870 |
Why?
|
Pulmonary Emphysema | 1 | 2023 | 2 | 0.860 |
Why?
|
Neoplasms | 10 | 2014 | 224 | 0.850 |
Why?
|
Tumor Cells, Cultured | 39 | 2005 | 110 | 0.850 |
Why?
|
Anticarcinogenic Agents | 8 | 2005 | 16 | 0.800 |
Why?
|
Neoplasm Proteins | 8 | 2007 | 45 | 0.780 |
Why?
|
Drug Delivery Systems | 5 | 2009 | 29 | 0.750 |
Why?
|
Breast Neoplasms | 11 | 2015 | 369 | 0.740 |
Why?
|
Gene Expression Regulation, Neoplastic | 7 | 2010 | 92 | 0.720 |
Why?
|
Lung | 10 | 2023 | 159 | 0.700 |
Why?
|
Growth Substances | 13 | 1996 | 29 | 0.700 |
Why?
|
Sputum | 14 | 2005 | 20 | 0.680 |
Why?
|
Cell Transformation, Neoplastic | 6 | 2003 | 29 | 0.660 |
Why?
|
Occupational Exposure | 2 | 2018 | 16 | 0.630 |
Why?
|
Systems Biology | 1 | 2018 | 5 | 0.630 |
Why?
|
Antineoplastic Agents | 9 | 2016 | 169 | 0.620 |
Why?
|
Radiation Exposure | 1 | 2018 | 9 | 0.620 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2018 | 11 | 0.620 |
Why?
|
Tobacco Use Disorder | 1 | 2018 | 16 | 0.620 |
Why?
|
Occupational Diseases | 1 | 2018 | 20 | 0.610 |
Why?
|
Myocardial Ischemia | 1 | 2018 | 37 | 0.600 |
Why?
|
Algorithms | 4 | 2015 | 347 | 0.590 |
Why?
|
Lipoxygenase Inhibitors | 5 | 2001 | 6 | 0.580 |
Why?
|
Radiographic Image Enhancement | 2 | 2015 | 27 | 0.570 |
Why?
|
Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 8 | 2003 | 8 | 0.550 |
Why?
|
United States | 15 | 2018 | 1943 | 0.540 |
Why?
|
Thoracic Surgery, Video-Assisted | 2 | 2015 | 21 | 0.540 |
Why?
|
Cell Division | 21 | 2003 | 79 | 0.530 |
Why?
|
Sensitivity and Specificity | 13 | 2016 | 472 | 0.520 |
Why?
|
DNA-Binding Proteins | 8 | 2003 | 249 | 0.510 |
Why?
|
Genes, ras | 8 | 2003 | 13 | 0.510 |
Why?
|
Imaging, Three-Dimensional | 2 | 2014 | 217 | 0.510 |
Why?
|
Gastrin-Releasing Peptide | 18 | 1999 | 18 | 0.500 |
Why?
|
Actuarial Analysis | 3 | 2012 | 8 | 0.500 |
Why?
|
Solitary Pulmonary Nodule | 1 | 2015 | 14 | 0.490 |
Why?
|
Pneumonectomy | 2 | 2015 | 76 | 0.480 |
Why?
|
Cyclooxygenase Inhibitors | 4 | 2004 | 27 | 0.470 |
Why?
|
Publishing | 1 | 2014 | 38 | 0.460 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2014 | 163 | 0.450 |
Why?
|
Growth Inhibitors | 6 | 1999 | 11 | 0.450 |
Why?
|
Smoking Cessation | 5 | 2014 | 41 | 0.450 |
Why?
|
Carcinoma, Squamous Cell | 5 | 2013 | 154 | 0.440 |
Why?
|
Genome, Human | 1 | 2013 | 36 | 0.430 |
Why?
|
Arachidonic Acid | 4 | 2001 | 14 | 0.430 |
Why?
|
Female | 43 | 2018 | 14273 | 0.420 |
Why?
|
Inflammation | 3 | 2009 | 261 | 0.420 |
Why?
|
Diagnostic Imaging | 3 | 2010 | 66 | 0.410 |
Why?
|
Bronchoalveolar Lavage Fluid | 4 | 1997 | 14 | 0.410 |
Why?
|
Radiation Dosage | 8 | 2017 | 35 | 0.410 |
Why?
|
Image Interpretation, Computer-Assisted | 3 | 2009 | 67 | 0.410 |
Why?
|
Prostaglandin-Endoperoxide Synthases | 4 | 2003 | 23 | 0.400 |
Why?
|
Insurance Benefits | 1 | 2012 | 1 | 0.400 |
Why?
|
Oligonucleotide Array Sequence Analysis | 3 | 2007 | 52 | 0.400 |
Why?
|
Oropharyngeal Neoplasms | 2 | 2004 | 19 | 0.400 |
Why?
|
Neoplasm Staging | 14 | 2008 | 315 | 0.390 |
Why?
|
Cost Savings | 1 | 2012 | 36 | 0.390 |
Why?
|
Mesoderm | 2 | 2010 | 18 | 0.390 |
Why?
|
Animals | 32 | 2010 | 3510 | 0.380 |
Why?
|
Heterogeneous-Nuclear Ribonucleoproteins | 2 | 2009 | 2 | 0.380 |
Why?
|
Male | 36 | 2018 | 13917 | 0.370 |
Why?
|
Bombesin | 9 | 1997 | 9 | 0.370 |
Why?
|
Transcription Factors | 2 | 2003 | 158 | 0.370 |
Why?
|
Epithelium | 3 | 2010 | 26 | 0.370 |
Why?
|
Reproducibility of Results | 8 | 2016 | 646 | 0.370 |
Why?
|
Medical Oncology | 4 | 2014 | 35 | 0.360 |
Why?
|
Precancerous Conditions | 5 | 2004 | 23 | 0.360 |
Why?
|
Spirometry | 1 | 2010 | 11 | 0.350 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2010 | 16 | 0.350 |
Why?
|
Proportional Hazards Models | 4 | 2010 | 332 | 0.340 |
Why?
|
Hyaluronic Acid | 1 | 2010 | 51 | 0.340 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2010 | 52 | 0.340 |
Why?
|
Gene Expression Profiling | 2 | 2007 | 128 | 0.330 |
Why?
|
Chemokines | 1 | 2009 | 20 | 0.330 |
Why?
|
Cost-Benefit Analysis | 5 | 2014 | 124 | 0.320 |
Why?
|
Inflammation Mediators | 1 | 2009 | 65 | 0.310 |
Why?
|
Cytokines | 1 | 2010 | 212 | 0.310 |
Why?
|
Arachidonate 5-Lipoxygenase | 2 | 1999 | 4 | 0.290 |
Why?
|
Drug Approval | 1 | 2007 | 7 | 0.290 |
Why?
|
Middle Aged | 27 | 2018 | 8403 | 0.290 |
Why?
|
Immunohistochemistry | 11 | 2005 | 341 | 0.280 |
Why?
|
Retinoids | 2 | 2005 | 5 | 0.280 |
Why?
|
RNA, Messenger | 12 | 2003 | 284 | 0.280 |
Why?
|
Isotretinoin | 4 | 2000 | 6 | 0.280 |
Why?
|
Risk Assessment | 7 | 2014 | 618 | 0.280 |
Why?
|
Indium Radioisotopes | 4 | 1999 | 5 | 0.280 |
Why?
|
Ketorolac | 2 | 2004 | 12 | 0.270 |
Why?
|
Chemoprevention | 2 | 2003 | 4 | 0.260 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 4 | 2017 | 29 | 0.260 |
Why?
|
Mice | 19 | 2000 | 1345 | 0.260 |
Why?
|
Practice Guidelines as Topic | 4 | 2014 | 284 | 0.260 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 3 | 2004 | 100 | 0.260 |
Why?
|
Clinical Trials as Topic | 9 | 2006 | 209 | 0.250 |
Why?
|
Head and Neck Neoplasms | 2 | 2005 | 146 | 0.250 |
Why?
|
DNA Mutational Analysis | 2 | 2003 | 53 | 0.240 |
Why?
|
Risk Factors | 11 | 2012 | 2224 | 0.240 |
Why?
|
Epithelial Cells | 4 | 2005 | 72 | 0.240 |
Why?
|
Leukoplakia, Oral | 1 | 2004 | 2 | 0.230 |
Why?
|
Signal Transduction | 5 | 2001 | 410 | 0.230 |
Why?
|
Antigens, Neoplasm | 9 | 1994 | 37 | 0.230 |
Why?
|
Transferrin | 3 | 1996 | 6 | 0.230 |
Why?
|
Mass Chest X-Ray | 1 | 2003 | 1 | 0.220 |
Why?
|
Insulin-Like Growth Factor I | 8 | 2001 | 52 | 0.220 |
Why?
|
Carrier Proteins | 3 | 1999 | 96 | 0.220 |
Why?
|
Prognosis | 10 | 2005 | 739 | 0.210 |
Why?
|
Cell Hypoxia | 1 | 2003 | 11 | 0.210 |
Why?
|
Isoenzymes | 3 | 2000 | 51 | 0.210 |
Why?
|
Apoptosis | 2 | 2001 | 177 | 0.210 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2003 | 20 | 0.210 |
Why?
|
Neoplasm Invasiveness | 4 | 2010 | 75 | 0.210 |
Why?
|
Down-Regulation | 1 | 2003 | 94 | 0.200 |
Why?
|
Survival Rate | 6 | 2016 | 308 | 0.200 |
Why?
|
Thoracic Surgical Procedures | 2 | 2012 | 9 | 0.200 |
Why?
|
Biomarkers | 6 | 2015 | 554 | 0.190 |
Why?
|
Quality Assurance, Health Care | 2 | 2017 | 33 | 0.190 |
Why?
|
Hydroxyeicosatetraenoic Acids | 1 | 2001 | 1 | 0.190 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2001 | 21 | 0.190 |
Why?
|
Neoplasms, Second Primary | 3 | 1997 | 37 | 0.190 |
Why?
|
Smoking Prevention | 3 | 2013 | 16 | 0.180 |
Why?
|
Adenocarcinoma | 6 | 1998 | 132 | 0.180 |
Why?
|
Ribonucleoproteins, Small Nuclear | 1 | 2000 | 2 | 0.180 |
Why?
|
Disease Management | 1 | 2001 | 97 | 0.180 |
Why?
|
Membrane Proteins | 2 | 1999 | 151 | 0.180 |
Why?
|
Software | 2 | 2014 | 63 | 0.180 |
Why?
|
Carcinoma | 2 | 1999 | 63 | 0.180 |
Why?
|
Databases, Factual | 2 | 2006 | 329 | 0.170 |
Why?
|
National Institutes of Health (U.S.) | 3 | 1996 | 20 | 0.170 |
Why?
|
Interleukin-6 | 1 | 2000 | 74 | 0.170 |
Why?
|
Aged | 19 | 2018 | 8501 | 0.170 |
Why?
|
Radioimmunodetection | 1 | 1999 | 1 | 0.170 |
Why?
|
Polymerase Chain Reaction | 8 | 2003 | 111 | 0.170 |
Why?
|
Multienzyme Complexes | 3 | 1999 | 27 | 0.170 |
Why?
|
Advisory Committees | 3 | 2014 | 19 | 0.160 |
Why?
|
Molecular Sequence Data | 14 | 1996 | 169 | 0.160 |
Why?
|
Nuclear Weapons | 1 | 2018 | 1 | 0.160 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 1998 | 34 | 0.160 |
Why?
|
Genetic Markers | 2 | 2000 | 36 | 0.150 |
Why?
|
Pancreatic Neoplasms | 2 | 1993 | 89 | 0.150 |
Why?
|
Receptors, Transferrin | 2 | 1996 | 4 | 0.150 |
Why?
|
Retinoblastoma Protein | 2 | 1995 | 10 | 0.150 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2005 | 311 | 0.150 |
Why?
|
Thoracic Neoplasms | 2 | 2017 | 8 | 0.150 |
Why?
|
Microscopy | 1 | 1997 | 10 | 0.140 |
Why?
|
Lymphoma | 4 | 1991 | 30 | 0.140 |
Why?
|
Adult | 15 | 2018 | 7336 | 0.140 |
Why?
|
Point Mutation | 1 | 1997 | 25 | 0.140 |
Why?
|
Gallium | 1 | 1996 | 2 | 0.130 |
Why?
|
Biological Specimen Banks | 1 | 1996 | 8 | 0.130 |
Why?
|
Military Medicine | 1 | 1996 | 8 | 0.130 |
Why?
|
Mice, Inbred BALB C | 6 | 2000 | 98 | 0.120 |
Why?
|
Protein Processing, Post-Translational | 5 | 1993 | 36 | 0.120 |
Why?
|
Indoles | 3 | 2001 | 35 | 0.120 |
Why?
|
Vascular Calcification | 1 | 2015 | 9 | 0.120 |
Why?
|
Radioimmunoassay | 5 | 1993 | 16 | 0.120 |
Why?
|
Coronary Vessels | 1 | 2015 | 33 | 0.120 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 7 | 2006 | 222 | 0.120 |
Why?
|
Base Sequence | 7 | 2003 | 90 | 0.120 |
Why?
|
Blotting, Northern | 5 | 2003 | 20 | 0.120 |
Why?
|
Health Policy | 1 | 2015 | 42 | 0.120 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 2 | 2005 | 12 | 0.120 |
Why?
|
Skin Neoplasms | 3 | 1991 | 66 | 0.120 |
Why?
|
Mutation | 5 | 2016 | 325 | 0.120 |
Why?
|
Mice, Nude | 8 | 1998 | 22 | 0.120 |
Why?
|
Mesothelioma | 1 | 1994 | 13 | 0.120 |
Why?
|
Physicians, Primary Care | 1 | 2014 | 7 | 0.120 |
Why?
|
Physician's Role | 1 | 2014 | 17 | 0.120 |
Why?
|
Electronic Nicotine Delivery Systems | 1 | 2014 | 2 | 0.110 |
Why?
|
Nuclear Proteins | 3 | 2003 | 80 | 0.110 |
Why?
|
International Agencies | 1 | 2014 | 3 | 0.110 |
Why?
|
Amino Acid Sequence | 10 | 1996 | 137 | 0.110 |
Why?
|
Lymph Nodes | 4 | 1991 | 66 | 0.110 |
Why?
|
Tobacco Use Cessation | 1 | 2013 | 1 | 0.110 |
Why?
|
Congresses as Topic | 1 | 2013 | 30 | 0.110 |
Why?
|
Neoplasm Metastasis | 2 | 2004 | 91 | 0.110 |
Why?
|
DNA Primers | 4 | 2003 | 46 | 0.110 |
Why?
|
Evidence-Based Medicine | 1 | 2014 | 170 | 0.110 |
Why?
|
Incidence | 3 | 2010 | 731 | 0.110 |
Why?
|
ErbB Receptors | 2 | 2010 | 52 | 0.110 |
Why?
|
Radiography, Thoracic | 2 | 2005 | 25 | 0.100 |
Why?
|
Neuropeptides | 2 | 1995 | 24 | 0.100 |
Why?
|
Genes, Tumor Suppressor | 3 | 2000 | 8 | 0.100 |
Why?
|
Eicosanoids | 2 | 2003 | 2 | 0.100 |
Why?
|
Codon | 4 | 2003 | 5 | 0.100 |
Why?
|
Patient Education as Topic | 2 | 2005 | 140 | 0.100 |
Why?
|
Drug Screening Assays, Antitumor | 4 | 1999 | 10 | 0.100 |
Why?
|
Oncogenes | 5 | 1993 | 9 | 0.100 |
Why?
|
Protein Binding | 2 | 2009 | 116 | 0.100 |
Why?
|
Research | 1 | 1992 | 38 | 0.100 |
Why?
|
Receptors, Retinoic Acid | 3 | 2000 | 3 | 0.100 |
Why?
|
Immunoenzyme Techniques | 6 | 1998 | 29 | 0.100 |
Why?
|
Dose-Response Relationship, Drug | 6 | 2000 | 325 | 0.090 |
Why?
|
Microsatellite Repeats | 2 | 2001 | 9 | 0.090 |
Why?
|
Combined Modality Therapy | 7 | 2016 | 281 | 0.090 |
Why?
|
Aerosols | 2 | 2002 | 22 | 0.090 |
Why?
|
Organoplatinum Compounds | 1 | 1990 | 1 | 0.090 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2010 | 3 | 0.090 |
Why?
|
Spain | 1 | 2010 | 7 | 0.090 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2010 | 7 | 0.090 |
Why?
|
Glucuronosyltransferase | 1 | 2010 | 4 | 0.090 |
Why?
|
Hyaluronan Synthases | 1 | 2010 | 5 | 0.090 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2010 | 20 | 0.090 |
Why?
|
Interleukin-1beta | 1 | 2010 | 51 | 0.090 |
Why?
|
Age Distribution | 1 | 2010 | 84 | 0.090 |
Why?
|
Sex Distribution | 1 | 2010 | 75 | 0.090 |
Why?
|
Data Collection | 1 | 1990 | 93 | 0.090 |
Why?
|
Protein Kinase Inhibitors | 1 | 2010 | 45 | 0.090 |
Why?
|
RNA, Neoplasm | 5 | 1999 | 10 | 0.090 |
Why?
|
Hyperplasia | 2 | 2000 | 17 | 0.080 |
Why?
|
Mice, Inbred A | 2 | 2000 | 2 | 0.080 |
Why?
|
Cell Line, Tumor | 1 | 2010 | 221 | 0.080 |
Why?
|
Quality of Life | 1 | 2014 | 600 | 0.080 |
Why?
|
Disease Progression | 4 | 2008 | 664 | 0.080 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2006 | 198 | 0.080 |
Why?
|
Phenotype | 1 | 2010 | 292 | 0.080 |
Why?
|
Tissue Distribution | 9 | 1998 | 32 | 0.080 |
Why?
|
Prospective Studies | 6 | 2008 | 1633 | 0.080 |
Why?
|
DNA, Neoplasm | 4 | 1998 | 18 | 0.080 |
Why?
|
Prevalence | 1 | 2010 | 435 | 0.080 |
Why?
|
Gastrins | 3 | 1993 | 4 | 0.080 |
Why?
|
Time Factors | 5 | 2000 | 1336 | 0.080 |
Why?
|
Immunoglobulin G | 3 | 1999 | 92 | 0.080 |
Why?
|
Gene Deletion | 2 | 2000 | 36 | 0.080 |
Why?
|
Liver Neoplasms | 3 | 1990 | 93 | 0.080 |
Why?
|
Radionuclide Imaging | 7 | 1991 | 38 | 0.070 |
Why?
|
5-Lipoxygenase-Activating Proteins | 2 | 1999 | 2 | 0.070 |
Why?
|
Drug Therapy, Computer-Assisted | 1 | 2007 | 4 | 0.070 |
Why?
|
Gene Targeting | 1 | 2007 | 8 | 0.070 |
Why?
|
Patient Selection | 2 | 2014 | 170 | 0.070 |
Why?
|
Mixed Function Oxygenases | 3 | 1999 | 4 | 0.070 |
Why?
|
Radiology Information Systems | 1 | 2007 | 2 | 0.070 |
Why?
|
United States Food and Drug Administration | 1 | 2007 | 22 | 0.070 |
Why?
|
Regression Analysis | 1 | 1988 | 255 | 0.070 |
Why?
|
Medical Laboratory Science | 1 | 2007 | 7 | 0.070 |
Why?
|
Prostatic Neoplasms | 2 | 1999 | 97 | 0.070 |
Why?
|
Models, Biological | 3 | 2004 | 311 | 0.070 |
Why?
|
Masoprocol | 2 | 1998 | 6 | 0.070 |
Why?
|
Carcinogens | 2 | 2000 | 10 | 0.070 |
Why?
|
Radiography | 1 | 2009 | 574 | 0.070 |
Why?
|
Genes, p53 | 2 | 2000 | 16 | 0.070 |
Why?
|
Age Factors | 4 | 2012 | 716 | 0.070 |
Why?
|
Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2006 | 2 | 0.070 |
Why?
|
Diagnosis, Differential | 3 | 2006 | 341 | 0.070 |
Why?
|
Europe | 1 | 2006 | 64 | 0.070 |
Why?
|
Iodine Radioisotopes | 3 | 1993 | 13 | 0.060 |
Why?
|
Culture Media, Conditioned | 3 | 2000 | 17 | 0.060 |
Why?
|
Cell Line | 12 | 1992 | 268 | 0.060 |
Why?
|
Bronchoalveolar Lavage | 2 | 2003 | 2 | 0.060 |
Why?
|
Ligases | 2 | 2003 | 10 | 0.060 |
Why?
|
HeLa Cells | 2 | 2003 | 39 | 0.060 |
Why?
|
Patient Care Planning | 1 | 2005 | 45 | 0.060 |
Why?
|
Apudoma | 1 | 1984 | 1 | 0.060 |
Why?
|
Angiomatosis | 1 | 1984 | 3 | 0.060 |
Why?
|
Pheochromocytoma | 1 | 1984 | 7 | 0.060 |
Why?
|
von Hippel-Lindau Disease | 1 | 1984 | 6 | 0.060 |
Why?
|
Liver | 3 | 2000 | 144 | 0.060 |
Why?
|
Spectrum Analysis | 1 | 2004 | 8 | 0.060 |
Why?
|
Mouth Mucosa | 1 | 2004 | 12 | 0.060 |
Why?
|
Mouth Neoplasms | 1 | 2004 | 20 | 0.060 |
Why?
|
Mouthwashes | 1 | 2004 | 6 | 0.060 |
Why?
|
Cell Proliferation | 1 | 2005 | 167 | 0.060 |
Why?
|
Placebos | 1 | 2004 | 68 | 0.060 |
Why?
|
Proteins | 2 | 1996 | 52 | 0.060 |
Why?
|
Protein Precursors | 5 | 1996 | 15 | 0.060 |
Why?
|
Cytodiagnosis | 2 | 1993 | 17 | 0.060 |
Why?
|
Rats | 5 | 2000 | 649 | 0.060 |
Why?
|
Administration, Inhalation | 2 | 2000 | 34 | 0.060 |
Why?
|
Endpoint Determination | 1 | 2003 | 21 | 0.050 |
Why?
|
Dinoprostone | 2 | 2000 | 16 | 0.050 |
Why?
|
Neovascularization, Pathologic | 1 | 2003 | 32 | 0.050 |
Why?
|
Immunotherapy | 3 | 2016 | 53 | 0.050 |
Why?
|
Hypoxia-Inducible Factor 1 | 1 | 2003 | 1 | 0.050 |
Why?
|
Artificial Intelligence | 1 | 2023 | 31 | 0.050 |
Why?
|
NF-kappa B | 1 | 2003 | 96 | 0.050 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2003 | 10 | 0.050 |
Why?
|
Double-Blind Method | 1 | 2004 | 396 | 0.050 |
Why?
|
Oxidative Stress | 1 | 2003 | 93 | 0.050 |
Why?
|
Indium | 3 | 1987 | 7 | 0.050 |
Why?
|
Enzyme Induction | 2 | 2000 | 18 | 0.050 |
Why?
|
Somatomedins | 2 | 1996 | 4 | 0.050 |
Why?
|
Radioisotopes | 3 | 1987 | 12 | 0.050 |
Why?
|
Amides | 3 | 1998 | 16 | 0.050 |
Why?
|
Anti-Inflammatory Agents | 1 | 2003 | 75 | 0.050 |
Why?
|
International Cooperation | 1 | 2002 | 22 | 0.050 |
Why?
|
Culture Media | 2 | 1996 | 29 | 0.050 |
Why?
|
Neoplasm Transplantation | 3 | 1998 | 12 | 0.050 |
Why?
|
Etoposide | 5 | 1996 | 25 | 0.050 |
Why?
|
Canada | 2 | 2012 | 48 | 0.050 |
Why?
|
Cisplatin | 5 | 1996 | 49 | 0.050 |
Why?
|
Survival Analysis | 5 | 2010 | 246 | 0.050 |
Why?
|
Proteomics | 1 | 2002 | 85 | 0.050 |
Why?
|
Population Surveillance | 2 | 2012 | 103 | 0.050 |
Why?
|
bcl-2-Associated X Protein | 1 | 2001 | 13 | 0.050 |
Why?
|
Societies, Medical | 2 | 2013 | 138 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2001 | 18 | 0.050 |
Why?
|
Pulmonary Surfactants | 2 | 1992 | 4 | 0.050 |
Why?
|
Proteolipids | 2 | 1992 | 5 | 0.050 |
Why?
|
Respiratory System | 2 | 1992 | 7 | 0.050 |
Why?
|
Ligands | 1 | 2001 | 37 | 0.050 |
Why?
|
Rats, Sprague-Dawley | 2 | 2000 | 322 | 0.050 |
Why?
|
Tumor Stem Cell Assay | 4 | 1999 | 4 | 0.050 |
Why?
|
Proto-Oncogene Proteins | 1 | 2001 | 31 | 0.050 |
Why?
|
Public Health | 1 | 2001 | 66 | 0.050 |
Why?
|
Biopsy | 3 | 2012 | 199 | 0.050 |
Why?
|
Predictive Value of Tests | 3 | 1997 | 443 | 0.050 |
Why?
|
Ribonucleoproteins | 1 | 2000 | 3 | 0.050 |
Why?
|
Binding Sites | 2 | 1993 | 65 | 0.050 |
Why?
|
Immunologic Tests | 1 | 2000 | 3 | 0.050 |
Why?
|
Drug Evaluation | 3 | 1990 | 19 | 0.050 |
Why?
|
Methylation | 1 | 2000 | 7 | 0.050 |
Why?
|
Loss of Heterozygosity | 1 | 2000 | 5 | 0.050 |
Why?
|
Comorbidity | 2 | 2012 | 457 | 0.040 |
Why?
|
HL-60 Cells | 1 | 2000 | 8 | 0.040 |
Why?
|
Receptors, Interleukin-6 | 1 | 2000 | 3 | 0.040 |
Why?
|
Paracrine Communication | 1 | 2000 | 4 | 0.040 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2000 | 17 | 0.040 |
Why?
|
Tetradecanoylphorbol Acetate | 1 | 2000 | 35 | 0.040 |
Why?
|
Interleukin-8 | 1 | 2000 | 17 | 0.040 |
Why?
|
Trans-Activators | 1 | 2000 | 23 | 0.040 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2000 | 16 | 0.040 |
Why?
|
Particle Size | 1 | 2000 | 48 | 0.040 |
Why?
|
STAT3 Transcription Factor | 1 | 2000 | 15 | 0.040 |
Why?
|
Interleukin-1 | 1 | 2000 | 48 | 0.040 |
Why?
|
Antibodies | 1 | 2000 | 48 | 0.040 |
Why?
|
Receptors, Neurotransmitter | 2 | 1991 | 5 | 0.040 |
Why?
|
RNA, Heterogeneous Nuclear | 1 | 1999 | 1 | 0.040 |
Why?
|
Fetus | 2 | 1998 | 37 | 0.040 |
Why?
|
Dogs | 2 | 1991 | 176 | 0.040 |
Why?
|
Cyclooxygenase 1 | 1 | 1999 | 6 | 0.040 |
Why?
|
Injections, Subcutaneous | 2 | 1991 | 24 | 0.040 |
Why?
|
Arachidonate 12-Lipoxygenase | 1 | 1999 | 3 | 0.040 |
Why?
|
Cyclooxygenase 2 | 1 | 1999 | 26 | 0.040 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 1999 | 19 | 0.040 |
Why?
|
Autocrine Communication | 1 | 1999 | 2 | 0.040 |
Why?
|
Cinnamates | 1 | 1999 | 8 | 0.040 |
Why?
|
Pilot Projects | 1 | 2000 | 392 | 0.040 |
Why?
|
Gene Expression Regulation | 1 | 2000 | 262 | 0.040 |
Why?
|
CD5 Antigens | 1 | 1998 | 1 | 0.040 |
Why?
|
Immunoconjugates | 1 | 1998 | 6 | 0.040 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 1 | 1998 | 5 | 0.040 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1998 | 14 | 0.040 |
Why?
|
Yttrium Radioisotopes | 1 | 1998 | 10 | 0.040 |
Why?
|
Capillaries | 1 | 1998 | 11 | 0.040 |
Why?
|
Mammals | 1 | 1998 | 18 | 0.040 |
Why?
|
Pregnancy | 2 | 1998 | 291 | 0.040 |
Why?
|
Colonic Neoplasms | 1 | 1999 | 56 | 0.040 |
Why?
|
Pyridines | 1 | 1998 | 36 | 0.040 |
Why?
|
Lipoxygenase | 1 | 1998 | 1 | 0.040 |
Why?
|
Benzoquinones | 1 | 1998 | 2 | 0.040 |
Why?
|
Quinolines | 1 | 1998 | 7 | 0.040 |
Why?
|
Bronchi | 1 | 1998 | 12 | 0.040 |
Why?
|
Insulin-Like Growth Factor II | 2 | 1996 | 5 | 0.040 |
Why?
|
Lung Diseases | 1 | 1998 | 42 | 0.040 |
Why?
|
Stimulation, Chemical | 2 | 2000 | 8 | 0.040 |
Why?
|
Cell Differentiation | 4 | 1992 | 127 | 0.040 |
Why?
|
Antigens, Surface | 4 | 1986 | 12 | 0.040 |
Why?
|
Remission Induction | 3 | 1996 | 80 | 0.040 |
Why?
|
beta Carotene | 1 | 1997 | 13 | 0.040 |
Why?
|
Physician-Patient Relations | 1 | 2017 | 37 | 0.040 |
Why?
|
History, 21st Century | 1 | 2017 | 18 | 0.040 |
Why?
|
Nurse-Patient Relations | 1 | 2017 | 57 | 0.040 |
Why?
|
Follow-Up Studies | 3 | 2006 | 1689 | 0.040 |
Why?
|
Positron-Emission Tomography | 2 | 2008 | 84 | 0.030 |
Why?
|
Liver Function Tests | 2 | 1988 | 19 | 0.030 |
Why?
|
Drug Resistance | 3 | 1994 | 37 | 0.030 |
Why?
|
In Vitro Techniques | 3 | 1992 | 157 | 0.030 |
Why?
|
Tomography, Emission-Computed | 1 | 1996 | 9 | 0.030 |
Why?
|
Diet | 2 | 2000 | 207 | 0.030 |
Why?
|
Communication | 1 | 2017 | 119 | 0.030 |
Why?
|
Peptide Fragments | 2 | 1996 | 71 | 0.030 |
Why?
|
Aminopterin | 1 | 1996 | 1 | 0.030 |
Why?
|
Folic Acid Antagonists | 1 | 1996 | 1 | 0.030 |
Why?
|
Dipyridamole | 1 | 1996 | 2 | 0.030 |
Why?
|
Computer Communication Networks | 1 | 1996 | 3 | 0.030 |
Why?
|
Maryland | 1 | 1996 | 7 | 0.030 |
Why?
|
Receptor, IGF Type 1 | 1 | 1996 | 19 | 0.030 |
Why?
|
Decision Making | 1 | 2017 | 203 | 0.030 |
Why?
|
Molecular Biology | 2 | 2007 | 11 | 0.030 |
Why?
|
Gene Expression | 1 | 1996 | 182 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 1 | 1996 | 57 | 0.030 |
Why?
|
Statistics, Nonparametric | 2 | 2008 | 119 | 0.030 |
Why?
|
Antigens, Differentiation | 1 | 1994 | 9 | 0.030 |
Why?
|
Cell Membrane | 2 | 1993 | 85 | 0.030 |
Why?
|
Receptors, Estrogen | 2 | 2005 | 56 | 0.030 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 1994 | 75 | 0.030 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2008 | 36 | 0.030 |
Why?
|
Atrial Natriuretic Factor | 1 | 1993 | 2 | 0.030 |
Why?
|
Arginine Vasopressin | 1 | 1993 | 2 | 0.030 |
Why?
|
Inositol | 1 | 1993 | 6 | 0.030 |
Why?
|
Environmental Exposure | 1 | 1993 | 17 | 0.030 |
Why?
|
Mitogens | 1 | 1992 | 5 | 0.030 |
Why?
|
Sodium | 1 | 1993 | 61 | 0.030 |
Why?
|
Severity of Illness Index | 1 | 2016 | 913 | 0.030 |
Why?
|
Uteroglobin | 1 | 1992 | 1 | 0.020 |
Why?
|
Amidine-Lyases | 1 | 1991 | 1 | 0.020 |
Why?
|
Chromogranins | 2 | 1988 | 3 | 0.020 |
Why?
|
Hormones | 1 | 1991 | 9 | 0.020 |
Why?
|
Gastric Acid | 1 | 1991 | 7 | 0.020 |
Why?
|
Tamoxifen | 1 | 1992 | 26 | 0.020 |
Why?
|
Treatment Outcome | 4 | 2006 | 3231 | 0.020 |
Why?
|
Antigens, Tumor-Associated, Carbohydrate | 1 | 1991 | 1 | 0.020 |
Why?
|
Chromosome Aberrations | 1 | 1991 | 9 | 0.020 |
Why?
|
Retrospective Studies | 2 | 1992 | 3220 | 0.020 |
Why?
|
Tretinoin | 1 | 1991 | 13 | 0.020 |
Why?
|
Chromosome Disorders | 1 | 1991 | 10 | 0.020 |
Why?
|
Cluster Analysis | 1 | 1991 | 39 | 0.020 |
Why?
|
Palliative Care | 2 | 1996 | 99 | 0.020 |
Why?
|
Adenoma | 1 | 1992 | 56 | 0.020 |
Why?
|
Injections | 1 | 1991 | 43 | 0.020 |
Why?
|
Blotting, Western | 3 | 1996 | 140 | 0.020 |
Why?
|
Carboplatin | 1 | 1990 | 20 | 0.020 |
Why?
|
Insulin | 2 | 1988 | 83 | 0.020 |
Why?
|
Up-Regulation | 2 | 2001 | 150 | 0.020 |
Why?
|
Chromosome Deletion | 2 | 1990 | 14 | 0.020 |
Why?
|
Glycosphingolipids | 1 | 1989 | 1 | 0.020 |
Why?
|
Tumor Burden | 1 | 2010 | 25 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2010 | 85 | 0.020 |
Why?
|
SEER Program | 1 | 2010 | 37 | 0.020 |
Why?
|
Glycolipids | 2 | 1986 | 2 | 0.020 |
Why?
|
Models, Statistical | 1 | 2010 | 120 | 0.020 |
Why?
|
Epidermal Growth Factor | 1 | 1989 | 27 | 0.020 |
Why?
|
Mating Factor | 1 | 1989 | 1 | 0.020 |
Why?
|
Chemistry | 1 | 1989 | 2 | 0.020 |
Why?
|
Chemical Phenomena | 1 | 1989 | 4 | 0.020 |
Why?
|
Saccharomyces cerevisiae | 1 | 1989 | 17 | 0.020 |
Why?
|
Registries | 1 | 2010 | 170 | 0.020 |
Why?
|
Glutaral | 1 | 1988 | 1 | 0.020 |
Why?
|
Polyvinyl Chloride | 1 | 1988 | 1 | 0.020 |
Why?
|
Fixatives | 1 | 1988 | 5 | 0.020 |
Why?
|
Aromatic-L-Amino-Acid Decarboxylases | 1 | 1988 | 1 | 0.020 |
Why?
|
Dopa Decarboxylase | 1 | 1988 | 1 | 0.020 |
Why?
|
Cytoplasmic Granules | 1 | 1988 | 3 | 0.020 |
Why?
|
Neurosecretory Systems | 1 | 1988 | 9 | 0.020 |
Why?
|
Random Allocation | 1 | 1988 | 116 | 0.020 |
Why?
|
Tetrazolium Salts | 1 | 1988 | 2 | 0.020 |
Why?
|
Spectrophotometry | 1 | 1988 | 4 | 0.020 |
Why?
|
Selenium | 1 | 1988 | 9 | 0.020 |
Why?
|
Thiazoles | 1 | 1988 | 19 | 0.020 |
Why?
|
Models, Theoretical | 1 | 1988 | 76 | 0.020 |
Why?
|
Antibody Formation | 1 | 1988 | 16 | 0.020 |
Why?
|
Estradiol | 1 | 1988 | 33 | 0.020 |
Why?
|
Hydrocortisone | 1 | 1988 | 35 | 0.020 |
Why?
|
Radiopharmaceuticals | 1 | 2008 | 48 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2008 | 126 | 0.020 |
Why?
|
Contrast Media | 1 | 2008 | 68 | 0.020 |
Why?
|
Databases, Protein | 1 | 2007 | 1 | 0.020 |
Why?
|
Databases as Topic | 1 | 2007 | 14 | 0.020 |
Why?
|
Histocompatibility Antigens Class II | 1 | 1987 | 6 | 0.020 |
Why?
|
Nerve Tissue Proteins | 1 | 1988 | 140 | 0.020 |
Why?
|
Bronchoscopy | 1 | 1987 | 24 | 0.020 |
Why?
|
Spleen | 1 | 1987 | 32 | 0.020 |
Why?
|
Research Design | 1 | 1988 | 188 | 0.020 |
Why?
|
Chromatography, High Pressure Liquid | 2 | 1996 | 13 | 0.020 |
Why?
|
Vincristine | 2 | 1996 | 17 | 0.020 |
Why?
|
Gene Amplification | 1 | 1986 | 18 | 0.020 |
Why?
|
Cyclophosphamide | 2 | 1996 | 43 | 0.020 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 2 | 1996 | 26 | 0.020 |
Why?
|
Doxorubicin | 2 | 1996 | 47 | 0.020 |
Why?
|
Methotrexate | 2 | 1996 | 34 | 0.020 |
Why?
|
beta 2-Microglobulin | 1 | 1985 | 1 | 0.020 |
Why?
|
Avidin | 1 | 1985 | 1 | 0.020 |
Why?
|
Ovalbumin | 1 | 1985 | 6 | 0.020 |
Why?
|
Biotin | 1 | 1985 | 7 | 0.020 |
Why?
|
HLA Antigens | 1 | 1985 | 16 | 0.020 |
Why?
|
Ki-67 Antigen | 1 | 2005 | 15 | 0.020 |
Why?
|
Pedigree | 1 | 1984 | 48 | 0.010 |
Why?
|
Stromal Cells | 1 | 2005 | 28 | 0.010 |
Why?
|
Lewis X Antigen | 1 | 1984 | 1 | 0.010 |
Why?
|
Genes, Dominant | 1 | 1984 | 10 | 0.010 |
Why?
|
Receptors, Bombesin | 3 | 1991 | 3 | 0.010 |
Why?
|
Oligosaccharides | 1 | 1984 | 15 | 0.010 |
Why?
|
Sulfur | 1 | 1984 | 2 | 0.010 |
Why?
|
Technetium Tc 99m Sulfur Colloid | 1 | 1984 | 5 | 0.010 |
Why?
|
Technetium | 1 | 1984 | 4 | 0.010 |
Why?
|
Cell Survival | 2 | 1998 | 110 | 0.010 |
Why?
|
Scattering, Radiation | 1 | 2004 | 36 | 0.010 |
Why?
|
Microscopy, Electron | 2 | 1998 | 61 | 0.010 |
Why?
|
Monte Carlo Method | 1 | 2004 | 52 | 0.010 |
Why?
|
Carcinoma, Bronchogenic | 1 | 1984 | 4 | 0.010 |
Why?
|
Binding Sites, Antibody | 1 | 1983 | 2 | 0.010 |
Why?
|
Antigen-Antibody Reactions | 1 | 1983 | 5 | 0.010 |
Why?
|
Computer Simulation | 1 | 2004 | 183 | 0.010 |
Why?
|
Immunoblotting | 2 | 1996 | 50 | 0.010 |
Why?
|
Drug Synergism | 2 | 1996 | 40 | 0.010 |
Why?
|
Brain Neoplasms | 2 | 1996 | 76 | 0.010 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2002 | 6 | 0.010 |
Why?
|
Guidelines as Topic | 1 | 2002 | 61 | 0.010 |
Why?
|
Epitopes | 2 | 1996 | 44 | 0.010 |
Why?
|
Rabbits | 2 | 1996 | 184 | 0.010 |
Why?
|
Transcription, Genetic | 2 | 1996 | 100 | 0.010 |
Why?
|
Pulmonary Surfactant-Associated Proteins | 2 | 1992 | 2 | 0.010 |
Why?
|
Mice, Inbred SENCAR | 1 | 2000 | 1 | 0.010 |
Why?
|
Transglutaminases | 1 | 2000 | 2 | 0.010 |
Why?
|
GTP-Binding Proteins | 1 | 2000 | 10 | 0.010 |
Why?
|
Analysis of Variance | 2 | 1991 | 256 | 0.010 |
Why?
|
Receptors, Cell Surface | 2 | 1992 | 37 | 0.010 |
Why?
|
Ditiocarb | 1 | 1999 | 1 | 0.010 |
Why?
|
Fatty Acids, Monounsaturated | 1 | 1999 | 2 | 0.010 |
Why?
|
Hygromycin B | 1 | 1999 | 2 | 0.010 |
Why?
|
Oligonucleotides, Antisense | 1 | 1999 | 11 | 0.010 |
Why?
|
Histocytochemistry | 2 | 1992 | 16 | 0.010 |
Why?
|
Radioimmunotherapy | 1 | 1998 | 1 | 0.010 |
Why?
|
Transfection | 1 | 1999 | 112 | 0.010 |
Why?
|
Lymphocyte Subsets | 1 | 1998 | 7 | 0.010 |
Why?
|
Cell Death | 1 | 1998 | 40 | 0.010 |
Why?
|
Chromogranin A | 2 | 1988 | 10 | 0.010 |
Why?
|
Carbohydrate Sequence | 2 | 1989 | 5 | 0.010 |
Why?
|
Transplantation, Heterologous | 2 | 1990 | 17 | 0.010 |
Why?
|
Proto-Oncogenes | 2 | 1990 | 2 | 0.010 |
Why?
|
Tin | 1 | 1997 | 1 | 0.010 |
Why?
|
Mining | 1 | 1997 | 3 | 0.010 |
Why?
|
China | 1 | 1997 | 46 | 0.010 |
Why?
|
Calcium | 2 | 1991 | 364 | 0.010 |
Why?
|
Deoxyglucose | 1 | 1996 | 2 | 0.010 |
Why?
|
Fluorine Radioisotopes | 1 | 1996 | 5 | 0.010 |
Why?
|
Breast | 1 | 1996 | 22 | 0.010 |
Why?
|
Cyanogen Bromide | 1 | 1996 | 1 | 0.010 |
Why?
|
Chromatography, Ion Exchange | 1 | 1996 | 5 | 0.010 |
Why?
|
Peptide Mapping | 1 | 1996 | 4 | 0.010 |
Why?
|
T-Lymphocytes | 2 | 1987 | 88 | 0.010 |
Why?
|
Phantoms, Imaging | 1 | 1996 | 37 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 1999 | 333 | 0.010 |
Why?
|
Mammography | 1 | 1996 | 41 | 0.010 |
Why?
|
Cranial Irradiation | 1 | 1996 | 13 | 0.010 |
Why?
|
Lomustine | 1 | 1996 | 1 | 0.010 |
Why?
|
Mechlorethamine | 1 | 1996 | 1 | 0.010 |
Why?
|
Nucleosides | 1 | 1996 | 2 | 0.010 |
Why?
|
Sequence Analysis | 1 | 1996 | 3 | 0.010 |
Why?
|
Carmustine | 1 | 1996 | 2 | 0.010 |
Why?
|
Thymidine | 1 | 1996 | 6 | 0.010 |
Why?
|
Immune Sera | 1 | 1996 | 5 | 0.010 |
Why?
|
Depression, Chemical | 1 | 1996 | 5 | 0.010 |
Why?
|
Sequence Alignment | 1 | 1996 | 18 | 0.010 |
Why?
|
Cross Reactions | 1 | 1996 | 10 | 0.010 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 1996 | 22 | 0.010 |
Why?
|
Biological Transport | 1 | 1996 | 38 | 0.010 |
Why?
|
Antibody Specificity | 1 | 1996 | 32 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 1996 | 36 | 0.010 |
Why?
|
Protein Conformation | 1 | 1996 | 69 | 0.010 |
Why?
|
Radiotherapy Dosage | 1 | 1996 | 110 | 0.010 |
Why?
|
Cause of Death | 1 | 1996 | 63 | 0.010 |
Why?
|
Specimen Handling | 1 | 1996 | 43 | 0.010 |
Why?
|
Blotting, Southern | 1 | 1995 | 3 | 0.010 |
Why?
|
Culture Media, Serum-Free | 1 | 1995 | 6 | 0.010 |
Why?
|
Chromatography, Gel | 1 | 1995 | 8 | 0.010 |
Why?
|
Homozygote | 1 | 1995 | 17 | 0.010 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 1995 | 17 | 0.010 |
Why?
|
Hemoglobins | 1 | 1996 | 72 | 0.010 |
Why?
|
Serum Albumin | 1 | 1995 | 19 | 0.010 |
Why?
|
Triglycerides | 1 | 1995 | 57 | 0.010 |
Why?
|
Drug Therapy | 1 | 1995 | 9 | 0.010 |
Why?
|
Antigen-Antibody Complex | 2 | 1985 | 5 | 0.010 |
Why?
|
Leukopenia | 1 | 1994 | 5 | 0.010 |
Why?
|
Thrombocytopenia | 1 | 1994 | 20 | 0.010 |
Why?
|
Proliferating Cell Nuclear Antigen | 1 | 1994 | 8 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 1994 | 152 | 0.010 |
Why?
|
Radiation Tolerance | 1 | 1994 | 6 | 0.010 |
Why?
|
Adolescent | 2 | 1994 | 2076 | 0.010 |
Why?
|
Neoplastic Stem Cells | 1 | 1994 | 6 | 0.010 |
Why?
|
Lymphatic Metastasis | 1 | 1994 | 81 | 0.010 |
Why?
|
Weight Loss | 1 | 1994 | 105 | 0.010 |
Why?
|
Ribonucleases | 1 | 1993 | 7 | 0.010 |
Why?
|
Inappropriate ADH Syndrome | 1 | 1993 | 2 | 0.010 |
Why?
|
Hyponatremia | 1 | 1993 | 8 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2001 | 4459 | 0.010 |
Why?
|
Infant | 1 | 1994 | 529 | 0.010 |
Why?
|
Chemotherapy, Adjuvant | 1 | 1992 | 69 | 0.010 |
Why?
|
Staining and Labeling | 1 | 1992 | 16 | 0.010 |
Why?
|
Child, Preschool | 1 | 1994 | 640 | 0.010 |
Why?
|
Lyases | 1 | 1991 | 7 | 0.010 |
Why?
|
Exons | 1 | 1992 | 29 | 0.010 |
Why?
|
Infant, Newborn | 1 | 1994 | 588 | 0.010 |
Why?
|
Glycine | 1 | 1991 | 12 | 0.010 |
Why?
|
Genetic Testing | 1 | 1992 | 56 | 0.010 |
Why?
|
Polymorphism, Restriction Fragment Length | 1 | 1991 | 4 | 0.010 |
Why?
|
Chromosome Banding | 1 | 1991 | 1 | 0.010 |
Why?
|
Karyotyping | 1 | 1991 | 8 | 0.010 |
Why?
|
Chromosome Mapping | 1 | 1991 | 26 | 0.010 |
Why?
|
Pleural Effusion | 1 | 1991 | 11 | 0.010 |
Why?
|
Alleles | 1 | 1991 | 190 | 0.010 |
Why?
|
Pulmonary Surfactant-Associated Protein A | 1 | 1990 | 1 | 0.010 |
Why?
|
DNA Probes | 1 | 1990 | 7 | 0.010 |
Why?
|
Dexamethasone | 1 | 1990 | 34 | 0.010 |
Why?
|
Glycoproteins | 1 | 1990 | 43 | 0.010 |
Why?
|
Hormones, Ectopic | 1 | 1990 | 1 | 0.010 |
Why?
|
Paraneoplastic Endocrine Syndromes | 1 | 1990 | 1 | 0.010 |
Why?
|
Antibodies, Neoplasm | 1 | 1990 | 13 | 0.010 |
Why?
|
Carbohydrate Conformation | 1 | 1989 | 5 | 0.010 |
Why?
|
Body Fluids | 1 | 1990 | 13 | 0.010 |
Why?
|
Child | 1 | 1994 | 1277 | 0.010 |
Why?
|
Carcinoembryonic Antigen | 1 | 1988 | 4 | 0.000 |
Why?
|
Leucine | 1 | 1988 | 10 | 0.000 |
Why?
|
Phosphopyruvate Hydratase | 1 | 1988 | 12 | 0.000 |
Why?
|
Peptide Biosynthesis | 1 | 1988 | 1 | 0.000 |
Why?
|
Carcinoid Tumor | 1 | 1988 | 5 | 0.000 |
Why?
|
Type C Phospholipases | 1 | 1988 | 8 | 0.000 |
Why?
|
Cell Communication | 1 | 1988 | 20 | 0.000 |
Why?
|
Cytoplasm | 1 | 1988 | 30 | 0.000 |
Why?
|
Receptor, Insulin | 1 | 1988 | 1 | 0.000 |
Why?
|
Receptors, Somatomedin | 1 | 1988 | 4 | 0.000 |
Why?
|
Immunoglobulin Isotypes | 1 | 1987 | 3 | 0.000 |
Why?
|
Immunization | 1 | 1987 | 15 | 0.000 |
Why?
|
Immunoglobulin M | 1 | 1987 | 14 | 0.000 |
Why?
|
Fluorescent Antibody Technique | 1 | 1987 | 55 | 0.000 |
Why?
|
Whole-Body Counting | 1 | 1987 | 2 | 0.000 |
Why?
|
Lymphatic System | 1 | 1987 | 4 | 0.000 |
Why?
|
Drug Carriers | 1 | 1987 | 7 | 0.000 |
Why?
|
Mycosis Fungoides | 1 | 1987 | 5 | 0.000 |
Why?
|
P Blood-Group System | 1 | 1986 | 1 | 0.000 |
Why?
|
Gangliosides | 1 | 1986 | 6 | 0.000 |
Why?
|
ABO Blood-Group System | 1 | 1986 | 5 | 0.000 |
Why?
|
Kinetics | 1 | 1987 | 179 | 0.000 |
Why?
|
Melanoma | 1 | 1987 | 52 | 0.000 |
Why?
|
Cell Separation | 1 | 1986 | 28 | 0.000 |
Why?
|
Cell Cycle | 1 | 1986 | 32 | 0.000 |
Why?
|
Postoperative Complications | 1 | 1992 | 827 | 0.000 |
Why?
|
Cytogenetics | 1 | 1986 | 1 | 0.000 |
Why?
|
Flow Cytometry | 1 | 1986 | 107 | 0.000 |
Why?
|
Binding, Competitive | 1 | 1985 | 21 | 0.000 |
Why?
|
Genes, MHC Class II | 1 | 1985 | 1 | 0.000 |
Why?
|
Interferons | 1 | 1985 | 7 | 0.000 |
Why?
|
HLA-B Antigens | 1 | 1985 | 8 | 0.000 |
Why?
|
HLA-A Antigens | 1 | 1985 | 13 | 0.000 |
Why?
|
HLA-C Antigens | 1 | 1985 | 10 | 0.000 |
Why?
|
Peroxidase | 1 | 1985 | 15 | 0.000 |
Why?
|
Peroxidases | 1 | 1985 | 7 | 0.000 |
Why?
|
Rats, Inbred Strains | 1 | 1984 | 23 | 0.000 |
Why?
|
Aging | 1 | 1992 | 1429 | 0.000 |
Why?
|